Affinivax
Biotechnology company that developed next-generation vaccines using proprietary MAPS (Multiple Antigen Presenting System) technology. Acquired by GSK in 2022 for $3.3 billion.
Notes
Affinivax was a clinical-stage biotechnology company focused on developing next-generation vaccines for infectious diseases. The company's proprietary MAPS (Multiple Antigen Presenting System) technology platform enabled the creation of vaccines that could generate both antibody and T cell-mediated immune responses.
Acquired by GlaxoSmithKline (GSK) in June 2022 for $3.3 billion ($2.1 billion upfront plus up to $1.2 billion in milestone payments). The acquisition provided GSK with the MAPS technology platform and AFX3772, a pneumococcal vaccine candidate in Phase 2 development.
Team
- Steven Brugger - Co-founder & Former CEO
- LinkedIn: linkedin.com/in/stevenbrugger
- Richard Malley, M.D. - Co-founder & Chief Scientific Advisor (Boston Children's Hospital)
- Yingda Xu, Ph.D. - Former Chief Scientific Officer
Additional Research Findings
- MAPS technology platform combines polysaccharide and protein antigens
- Lead candidate AFX3772 targeted 24 pneumococcal serotypes
- Technology licensed from Boston Children's Hospital
- Raised over $200 million before acquisition
- GSK acquisition aimed to strengthen pneumococcal vaccine portfolio
- Technology now integrated into GSK Vaccines R&D pipeline
- MAPS platform being applied to multiple vaccine development programs